Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has paid $7.5m as regulatory milestone to Auxilium Pharmaceuticals related to the first sale of Xiapex in Germany as a treatment for Dupuytren's contracture.
Subscribe to our email newsletter
Xiapex is a new non-surgical injectable treatment option for Dupuytren’s contracture in adult patients with a palpable cord.
So far, Pfizer has paid $52.5m of regulatory milestones to Auxilium in connection with the Dupuytren’s contracture indication.
Further, Pfizer is also responsible to pay $22.5m in additional regulatory milestone payments for this indication.
Pfizer will pay remaining $22.5m in $7.5m increments to Auxilium, following its first sale of Xiapex in each of the remaining major markets of the EU.
Auxilium president and CEO Armando Anido said they are pleased to see their close collaboration with Pfizer bring Xiapex, a novel, non-surgical alternative to new patients suffering from the debilitating effects of Dupuytren’s contracture in additional European countries.